Akesobio Australia Pty Ltd clinical trials
A country office of Akeso
The registry lists 9 studies whose lead sponsor is Akesobio Australia Pty Ltd. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Dec 4, 2025.
Registry sponsor names on this page
- Akesobio Australia Pty Ltd9 studies
Something wrong with this grouping? Tell us on the Akeso page.
Studies
Recruiting first, then most recently updated. Showing 9 of 9. All Akeso studies →
- A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK127 in Combination With AK104 in Advanced and Metastatic Solid TumoursCompletedNCT05021120Early Phase 1
Sponsor listed in the registry: Akesobio Australia Pty Ltd
- Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid TumorsCompletedNCT03352531Phase 1
Sponsor listed in the registry: Akesobio Australia Pty Ltd
- A Study of AK119 (Anti-CD73 Antibody), a Treatment for COVID-19, in Healthy SubjectsCompletedNCT04516564Phase 1
Sponsor listed in the registry: Akesobio Australia Pty Ltd
- A Study of AK112, a PD-1/VEGF Bispecific Antibody, for Advanced Solid TumorsCompletedNCT04047290Phase 1
Sponsor listed in the registry: Akesobio Australia Pty Ltd
- A Study of AK111 in Healthy SubjectsCompletedNCT03622021Phase 1
Sponsor listed in the registry: Akesobio Australia Pty Ltd
- Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK104 in Subjects With Advanced Solid TumorsCompletedNCT03261011Phase 1
Sponsor listed in the registry: Akesobio Australia Pty Ltd
- Phase 2 Study of Efficacy and Safety of AK120, in Subjects With Moderate-to-Severe Atopic DermatitisTerminatedNCT05048056Phase 2
Sponsor listed in the registry: Akesobio Australia Pty Ltd
- A Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of AK117 as Monotherapy or in Combination With AK104CompletedNCT04349969Phase 1
Sponsor listed in the registry: Akesobio Australia Pty Ltd
- A Study of AK120 (IL-4Rα) in Healthy Subjects and Subjects With Moderate- to- Severe Atopic DermatitisCompletedNCT04256174Phase 1
Sponsor listed in the registry: Akesobio Australia Pty Ltd